DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome)) Uses, Dosage, Side Effects and more

DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome)) is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).

Trade Name DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome))
Generic Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec Other Names Dna (recombinant vaccinia virus strain livp clone gl-onc1), DNA (synthetic vaccinia virus oncolytic-strain GLV-1h68 (complete genome)), Olvimulogene nanivacirepvec
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share